白血病·淋巴瘤
白血病·淋巴瘤
백혈병·림파류
JOURNAL OF LEUKEMIA & LYMPHOMA
2014年
6期
343-346
,共4页
沈克锋%刘启发%孙竞%江千里%徐丹%张钰%范志平%黄芬%周红升
瀋剋鋒%劉啟髮%孫競%江韆裏%徐丹%張鈺%範誌平%黃芬%週紅升
침극봉%류계발%손경%강천리%서단%장옥%범지평%황분%주홍승
伊马替尼%白血病,髓系,慢性%造血干细胞移植%造血功能重建%心力衰竭%移植相关早期并发症
伊馬替尼%白血病,髓繫,慢性%造血榦細胞移植%造血功能重建%心力衰竭%移植相關早期併髮癥
이마체니%백혈병,수계,만성%조혈간세포이식%조혈공능중건%심력쇠갈%이식상관조기병발증
Imatinib%Leukemia,myelogenous,chronic%Hematopoietic stem cell transplantation%Hematopoietic reconstitution%Heart Failure%Early transplant-related complications
目的 研究移植前伊马替尼治疗对慢性粒细胞白血病(CML)异基因移植患者造血重建及移植相关早期并发症的影响.方法 回顾性分析南方医科大学南方医院2003年5月至2013年5月97例行异基因移植CML患者病例资料,分为伊马替尼组(27例)与对照组(70例),分析两组间造血重建时间、早期预后以及急性心力衰竭、肝静脉闭塞病(HVOD)、移植物抗宿主病(GVHD)、出血性膀胱炎、病原体感染等移植相关早期(+100天)并发症发生率.结果 两组间移植后造血重建时间以及HVOD、GVHD、出血性膀胱炎、病原体感染发生率差异均无统计学意义(P＞0.05).但伊马替尼组急性心力衰竭发生率较对照组高29.6％(8/27)比8.6％(6/70),P=0.02],且死亡或放弃治疗事件发生率也较对照组高[18.5％(5/27)比2.9％(2/70),P=0.02].结论 移植前伊马替尼治疗可能会增加CML异基因移植患者急性心衰发生率且一定程度上影响患者预后,但对造血重建时间以及HVOD、GVHD、出血性膀胱炎、病原体感染等移植相关早期并发症发生率无明显影响.
目的 研究移植前伊馬替尼治療對慢性粒細胞白血病(CML)異基因移植患者造血重建及移植相關早期併髮癥的影響.方法 迴顧性分析南方醫科大學南方醫院2003年5月至2013年5月97例行異基因移植CML患者病例資料,分為伊馬替尼組(27例)與對照組(70例),分析兩組間造血重建時間、早期預後以及急性心力衰竭、肝靜脈閉塞病(HVOD)、移植物抗宿主病(GVHD)、齣血性膀胱炎、病原體感染等移植相關早期(+100天)併髮癥髮生率.結果 兩組間移植後造血重建時間以及HVOD、GVHD、齣血性膀胱炎、病原體感染髮生率差異均無統計學意義(P＞0.05).但伊馬替尼組急性心力衰竭髮生率較對照組高29.6％(8/27)比8.6％(6/70),P=0.02],且死亡或放棄治療事件髮生率也較對照組高[18.5％(5/27)比2.9％(2/70),P=0.02].結論 移植前伊馬替尼治療可能會增加CML異基因移植患者急性心衰髮生率且一定程度上影響患者預後,但對造血重建時間以及HVOD、GVHD、齣血性膀胱炎、病原體感染等移植相關早期併髮癥髮生率無明顯影響.
목적 연구이식전이마체니치료대만성립세포백혈병(CML)이기인이식환자조혈중건급이식상관조기병발증적영향.방법 회고성분석남방의과대학남방의원2003년5월지2013년5월97례행이기인이식CML환자병례자료,분위이마체니조(27례)여대조조(70례),분석량조간조혈중건시간、조기예후이급급성심력쇠갈、간정맥폐새병(HVOD)、이식물항숙주병(GVHD)、출혈성방광염、병원체감염등이식상관조기(+100천)병발증발생솔.결과 량조간이식후조혈중건시간이급HVOD、GVHD、출혈성방광염、병원체감염발생솔차이균무통계학의의(P＞0.05).단이마체니조급성심력쇠갈발생솔교대조조고29.6％(8/27)비8.6％(6/70),P=0.02],차사망혹방기치료사건발생솔야교대조조고[18.5％(5/27)비2.9％(2/70),P=0.02].결론 이식전이마체니치료가능회증가CML이기인이식환자급성심쇠발생솔차일정정도상영향환자예후,단대조혈중건시간이급HVOD、GVHD、출혈성방광염、병원체감염등이식상관조기병발증발생솔무명현영향.
Objective To investigate the effects of exposure to imatinib prior to allogeneic hematopoietic stem cell transplantation (allo-HSCT) on hematopoietic reconstruction and early transplantrelated complications for chronic myeloid leukemia (CML) patients.Methods 97 CML patients' clinical data who underwent allo-HSCT in Nanfang Hospital from May 2003 to May 2013 were analyzed retrospectively.The patients were divided into imatinib group (27 patients) and control group (70 patients) and their hematopoietic reconstruction time,prognosis and the incidence of early transplant-related complications (±100 day) such as acute hearrtfailure,hepatic veno-occlusive disease (HVOD),graft versus host disease (GVHD),hemorrhagic cystitis and infections were compared.Results Compared with control group,imatinib group neither had a significantly longer hematopoietic reconstruction time nor higher incidence of HVOD,GVHD,hemorrhagic cystitis and infections (P ＞ 0.05).However,imatinib group tended to have a statistically higher incidence of acute hearrtfailure [29.6 ％ (8/27) vs 8.6 ％ (6/70),P =0.02] and higher rate of mortality and withdrawal of treatment [18.5 ％ (5/27) vs 2.9 ％ (2/70),P =0.02].Conclusions Imatinib treatment prior to transplantation probably increases the incidence of acute hearrtfailure and induces adverse prognosis.But it does not influence hematopoietic reconstruction or the incidence of early transplant-related complications such as HVOD,GVHD,hemorrhagic cystitis and infections.
